  Improvement of anti-tumor biotherapy effectiveness by modification of immune
response with histamine H2 receptor Cimetidinum (CM) was studied using the
experimental murine model of B16 F10 melanoma in vivo. It is shown that skin
melanoma biotherapy by antitumor whole-cell GM-CSF-producing vaccine with the
addition of CM (in dose of 25 mg/kg, daily for 5 days) increases preventive
effects of vaccination. 33 % of mice did not have tumor growth within 60 days
of observation. Average life span of animals exceeded those of the control
group up to 68 %. Using CM-combined bio-chemotherapy doesn't improve
therapeutic effect, however in the case of a monotherapeutic approach tendency
for increased average life-time and decreased metastatic processes in mice with
the developed tumors was noticed. Aquired data provides expediency to study the
further application of CM as adjuvant for skin melanoma vaccinotherapy, and
also the necessity to verify the immune status of an organism against the
complex bio-chemotherapy.
